ReviewMolecular therapy. Nucleic acids2025
MicroRNAs and synaptic dysfunction in Parkinson's disease.
Review in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fully Automated Azeotropic Drying-Free Synthesis of [Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a debilitating neurodegenerative condition. Synaptic dysfunctions are associated with the onset and progressive neurodegeneration exhibited in PD. Healthy, active synapses are a prerequisite for non-pathological neurotransmission. When neurotransmission becomes pathological, such as observed in neurodegenerative conditions like PD, the biomolecules found in and around such synapses need distinctive investigation. MicroRNAs (miRNAs) found in neuronal subcellular compartments, such as dendrites, pre-synaptic boutons, and synaptic vesicles, have been garnering attention in neurogenerative diseases. MiRNAs that modulate synaptic activity and synapse function are called synaptic miRNAs. Several miRNAs have been identified that regulate key synaptic proteins; however, information about synaptic miRNAs is largely unknown in PD. In this review, we focused on the most promising synaptic miRNAs, those that are critical for normal synapse function and play a crucial role in PD pathology. We also discussed the synaptic miRNA's interplay with PD-associated synaptic dysfunction. Investigating further how synaptic miRNAs impacts PD pathogenesis may uncover novel etiological information and potential pathways for treatments and a cure for PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.